Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    September 2017
  1. ALTUNDAG K
    Questions about lower inner zone tumors in early-stage breast cancer.
    Breast Cancer. 2017 Sep 14. doi: 10.1007/s12282-017-0801.
    PubMed     Text format    


    August 2017
  2. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Aug 31. doi: 10.1007/s12282-017-0798.
    PubMed     Text format     Abstract available


  3. YAMAGUCHI T, Mukai H, Akiyama F, Arihiro K, et al
    Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer. 2017 Aug 30. doi: 10.1007/s12282-017-0799.
    PubMed     Text format     Abstract available


  4. YANG J, Tang S, Zhou Y, Qiu J, et al
    Prognostic implication of the primary tumor location in early-stage breast cancer: focus on lower inner zone.
    Breast Cancer. 2017 Aug 18. doi: 10.1007/s12282-017-0797.
    PubMed     Text format     Abstract available


    July 2017
  5. YU Z, Guo X, Jiang Y, Teng L, et al
    Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
    Breast Cancer. 2017 Jul 28. doi: 10.1007/s12282-017-0794.
    PubMed     Text format     Abstract available


  6. NAKAMURA R, Yamamoto N, Miyaki T, Itami M, et al
    Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Breast Cancer. 2017 Jul 22. doi: 10.1007/s12282-017-0795.
    PubMed     Text format     Abstract available


  7. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Erratum to: Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jul 7. doi: 10.1007/s12282-017-0792.
    PubMed     Text format    


    June 2017
  8. NAKAI K, Xia W, Liao HW, Saito M, et al
    The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Breast Cancer. 2017 Jun 22. doi: 10.1007/s12282-017-0790.
    PubMed     Text format     Abstract available


  9. SEKIGUCHI K
    Controversies in the role of postmastectomy radiotherapy in breast cancer patients with one to three positive axillary nodes and safety of integrating radiotherapy and breast reconstruction.
    Breast Cancer. 2017 Jun 14. doi: 10.1007/s12282-017-0788.
    PubMed     Text format    


  10. YU X, Zhou S, Wang J, Zhang Q, et al
    Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies.
    Breast Cancer. 2017 Jun 10. doi: 10.1007/s12282-017-0789.
    PubMed     Text format     Abstract available


  11. TADA K, Nishioka K, Kikuchi Y, Niwa T, et al
    Post-mastectomy radiation therapy in breast cancer with 1-3 involved lymph nodes: the Pros.
    Breast Cancer. 2017 Jun 5. doi: 10.1007/s12282-017-0787.
    PubMed     Text format     Abstract available


    May 2017
  12. MIZOTA Y, Ohashi Y, Iwase T, Iwata H, et al
    Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan.
    Breast Cancer. 2017 May 25. doi: 10.1007/s12282-017-0784.
    PubMed     Text format     Abstract available


  13. MATSUDA N, Kida K, Ohde S, Suzuki K, et al
    Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
    Breast Cancer. 2017 May 23. doi: 10.1007/s12282-017-0782.
    PubMed     Text format     Abstract available


  14. TOMIOKA N, Azuma M, Ikarashi M, Yamamoto M, et al
    The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Breast Cancer. 2017 May 9. doi: 10.1007/s12282-017-0781.
    PubMed     Text format     Abstract available


    April 2017
  15. LEUTERITZ K, Weissflog G, Barthel Y, Brahler E, et al
    Therapeutic alliance and treatment outcome in psychodynamic psychotherapy of depressed breast cancer patients: the same old story or different from other populations?
    Breast Cancer. 2017 Apr 28. doi: 10.1007/s12282-017-0777.
    PubMed     Text format     Abstract available


  16. YAMAMOTO S, Maeda N, Nagashima Y, Kubo H, et al
    A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Breast Cancer. 2017 Apr 24. doi: 10.1007/s12282-017-0779.
    PubMed     Text format     Abstract available


  17. KITAYAMA H, Kondo T, Sugiyama J, Kurimoto K, et al
    High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Breast Cancer. 2017 Apr 22. doi: 10.1007/s12282-017-0778.
    PubMed     Text format     Abstract available


  18. GHEYBI MK, Farrokhi S, Ravanbod MR, Ostovar A, et al
    The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients.
    Breast Cancer. 2017 Apr 20. doi: 10.1007/s12282-017-0775.
    PubMed     Text format     Abstract available


  19. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Breast Cancer. 2017 Apr 19. doi: 10.1007/s12282-017-0774.
    PubMed     Text format     Abstract available


  20. HANAMURA T, Hayashi SI
    Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Breast Cancer. 2017 Apr 7. doi: 10.1007/s12282-017-0772.
    PubMed     Text format     Abstract available


  21. MALEK-HOSSEINI Z, Jelodar S, Talei A, Ghaderi A, et al
    Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size.
    Breast Cancer. 2017 Apr 5. doi: 10.1007/s12282-017-0773.
    PubMed     Text format     Abstract available


  22. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2017 Apr 4. doi: 10.1007/s12282-017-0771.
    PubMed     Text format    


    March 2017
  23. LIN WZ, Xu QN, Wang HB, Li XY, et al
    Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
    Breast Cancer. 2017 Mar 21. doi: 10.1007/s12282-017-0770.
    PubMed     Text format     Abstract available


  24. ALTUNDAG K
    Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
    Breast Cancer. 2017 Mar 8. doi: 10.1007/s12282-017-0767.
    PubMed     Text format    


  25. GALLI G, Tessari A, Di Cosimo S
    Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history.
    Breast Cancer. 2017 Mar 6. doi: 10.1007/s12282-017-0766.
    PubMed     Text format    


    February 2017
  26. KOGA C, Akiyoshi S, Ishida M, Nakamura Y, et al
    Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer. 2017 Feb 27. doi: 10.1007/s12282-017-0764.
    PubMed     Text format     Abstract available


  27. UOMORI T, Horimoto Y, Mogushi K, Matsuoka J, et al
    Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients.
    Breast Cancer. 2017 Feb 20. doi: 10.1007/s12282-017-0761.
    PubMed     Text format     Abstract available


  28. ALTUNDAG K
    Does longer disease-free interval affect the complete remission in metastatic breast cancer?
    Breast Cancer. 2017 Feb 16. doi: 10.1007/s12282-017-0762.
    PubMed     Text format    


    January 2017
  29. KOIKE Y, Ohta Y, Saitoh W, Yamashita T, et al
    Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Breast Cancer. 2017 Jan 31. doi: 10.1007/s12282-017-0757.
    PubMed     Text format     Abstract available


  30. LUO M, Ding L, Li Q, Yao H, et al
    miR-668 enhances the radioresistance of human breast cancer cell by targeting IkappaBalpha.
    Breast Cancer. 2017 Jan 30. doi: 10.1007/s12282-017-0756.
    PubMed     Text format     Abstract available


  31. INOUE M, Nakagomi H, Nakada H, Furuya K, et al
    Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Breast Cancer. 2017 Jan 20. doi: 10.1007/s12282-017-0753.
    PubMed     Text format     Abstract available


  32. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-016-0749.
    PubMed     Text format     Abstract available


  33. TANAKA S, Suzuki K, Sakaguchi M
    The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-017-0752.
    PubMed     Text format     Abstract available


  34. GALLI G, Tessari A, Porcu L, Bregni G, et al
    Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-017-0751.
    PubMed     Text format     Abstract available


  35. HALLAJIAN Z, Mahjoubi F, Nafissi N
    Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-016-0750.
    PubMed     Text format     Abstract available


  36. FUTAMURA M, Nagao Y, Ishihara K, Takeuchi M, et al
    Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Breast Cancer. 2017 Jan 3. doi: 10.1007/s12282-016-0748.
    PubMed     Text format     Abstract available


  37. SUGIE T, Toi M
    Antitumor immunity and advances in cancer immunotherapy.
    Breast Cancer. 2017;24:1-2.
    PubMed     Text format    


    December 2016
  38. PARK JH
    The effects of complex exercise on shoulder range of motion and pain for women with breast cancer-related lymphedema: a single-blind, randomized controlled trial.
    Breast Cancer. 2016 Dec 23. doi: 10.1007/s12282-016-0747.
    PubMed     Text format     Abstract available


    November 2016
  39. VELAEI K, Samadi N, Soltani S, Barazvan B, et al
    NFkappaBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  40. LI T, Liu Y, Xiao H, Xu G, et al
    Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  41. HOSSAIN A, Murshid GM, Zilani MN, Islam F, et al
    TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  42. GUVELI H, Guveli ME, Sen F, Oflaz S, et al
    Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  43. IMAMURA T, Yamamoto-Ibusuki M, Sueta A, Kubo T, et al
    Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
    Breast Cancer. 2016;23:876-885.
    PubMed     Text format     Abstract available


  44. YAMASHITA H, Ogiya A, Shien T, Horimoto Y, et al
    Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer. 2016;23:830-843.
    PubMed     Text format     Abstract available


  45. SHIMO A, Tsugawa K, Tsuchiya S, Yoshie R, et al
    Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution.
    Breast Cancer. 2016;23:851-860.
    PubMed     Text format     Abstract available


    October 2016
  46. MARUTHANILA VL, Elancheran R, Kunnumakkara AB, Kabilan S, et al
    Recent development of targeted approaches for the treatment of breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  47. TANE K, Egawa C, Takao S, Yamagami K, et al
    Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  48. TAN T, Zhang K, Chen W
    Erratum to: Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
    Breast Cancer. 2016.
    PubMed     Text format    


  49. YANG J, Tan Q, Fu Q, Zhou Y, et al
    Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    September 2016
  50. NAKADA H, Nakagomi H, Hirotsu Y, Amemiya K, et al
    A study of tumor heterogeneity in a case with breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  51. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  52. UEMATSU T
    Possible supplemental breast cancer screening modalities.
    Breast Cancer. 2016.
    PubMed     Text format    


    August 2016
  53. ZHANG X, Fan Y, Liu B, Qi X, et al
    Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  54. IKEDA T, Sugie T, Shimizu A, Toi M, et al
    Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  55. SAKAKIBARA J, Sakakibara M, Shiina N, Fujimori T, et al
    Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  56. IMOTO S, Yamauchi C, Komoike Y, Tsugawa K, et al
    Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  57. HSIEH WC, Lin C, Chen DR, Yu WF, et al
    Genetic polymorphisms in APE1 Asp148Glu(rs3136820) as a modifier of the background levels of abasic sites in human leukocytes derived from breast cancer patients and controls.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  58. LI J, Ren J, Sun W
    Systematic review of ixabepilone for treating metastatic breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    July 2016
  59. ANDRYSZAK P, Wilkosc M, Zurawski B, Izdebski P, et al
    Verbal fluency in breast cancer patients treated with chemotherapy.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  60. TAN T, Zhang K, Sun WC
    Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    June 2016
  61. NAGATA T, Shimada Y, Sekine S, Moriyama M, et al
    KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  62. EICHLER M, Singer S, Janni W, Harbeck N, et al
    Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  63. UEMATSU T
    The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  64. PORDELI M, Nakhjiri M, Safavi M, Ardestani SK, et al
    Anticancer effects of synthetic hexahydrobenzo [g]chromen-4-one derivatives on human breast cancer cell lines.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


    May 2016
  65. HONDA K, Takeshita K, Murotani K, Mitsuma A, et al
    Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


  66. MORIYA T
    The current topics of surgical pathology of breast cancer in Japan.
    Breast Cancer. 2016.
    PubMed     Text format    


  67. KACZYNSKA A, Herman-Antosiewicz A
    Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
    Breast Cancer. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: